Home Others Molecular Glues

Molecular Glues

Other Others Related Inhibitors

PROTAC Others Antineoplastic and Immunosuppressive Antibiotics Selection Antibiotics for Transfected Cell Antibiotics for Mammalian Cell Culture Antibiotics for Plant Cell Culture ADC Cytotoxin ADC Linker Drug-Linker Conjugates for ADC Hydrotropic Agents
Cat.No. Product Name Information Product Use Citations Product Validations
S1029 CC-5013 (Lenalidomide) Lenalidomide is a TNF-α secretion inhibitor with IC50 of 13 nM in PBMCs. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide promotes cleaved caspase-3 expression and inhibit VEGF expression and induces apoptosis.
Signal Transduct Target Ther, 2025, 10(1):29
Nat Commun, 2025, 16(1):3800
Cell Rep Med, 2025, S2666-3791(25)00102-8
Verified customer review of CC-5013 (Lenalidomide)
S1567 Pomalidomide (CC-4047) Pomalidomide inhibits LPS-induced TNF-α release with IC50 of 13 nM in PBMCs. Pomalidomide can be utilized in PROTAC as a ligand for targeting E3 ligase and inhibiting the E3 ligase protein cereblon (CRBN). Pomalidomide promotes apoptosis and cell cycle arrest.
Nat Commun, 2025, 16(1):6631
Cell Rep Med, 2025, S2666-3791(25)00102-8
J Med Virol, 2025, 97(8):e70537
Verified customer review of Pomalidomide (CC-4047)
S8760 Iberdomide (CC-220) Iberdomide (CC-220) is a novel oral immunomodulatory compound that targets cereblon, part of the CRL4CRBN E3 ubiquitin ligase complex, with an IC50 of 60 nM in a competitive TR-FRET assay. Iberdomide (CC-220) induces apoptosis with antitumor and immunostimulatory activities.
Cell Rep Med, 2025, S2666-3791(25)00102-8
J Med Virol, 2025, 97(8):e70537
Cancer Res, 2025, 10.1158/0008-5472.CAN-24-1136
E5871New VAV1 degrader-3 VAV1 degrader-3 (MRT-6160) is an orally active molecular glue degrader of VAV1 with a DC50 of 7 nM. It suppresses immune activation, proliferation, and cytokine production, inhibiting disease progression in inflammatory and autoimmune models like encephalomyelitis (EAE) and Collagen-induced arthritis (CIA).
E5854New XYD049 XYD049 (compound 7d) is a CRBN-based molecular glue targeting GSPT1 (DC50=19 nM), applicable for studying MYC-driven castration-resistant prostate cancer (CRPC). It demonstrates potent growth inhibition of 22Rv1 cells (IC50=7 nM) and exhibits in vivo antitumor activity. This compound downregulates CRPC-associated oncogenes (AR, AR-v7, PSA, c-Myc) in 22Rv1 cells. Structurally, it consists of: 1) a molecular glue linker (NH2-C5-NH-Boc), 2) a CRBN-recruiting E3 ligase ligand (Thalidomide 4-fluoride), and 3) a GSPT1-targeting moiety (GSPT1 ligand-1). The E3 ligase ligand-linker combination forms conjugate 158.
E1810 dCeMM1 dCeMM1 is a degrader of RBM39. This compound functions by altering the activity of the CRL4DCAF15 ligase, and also decreases RBM39 expression levels in wild-type KBM7 cells.
S1193 Thalidomide Thalidomide was introduced as a sedative drug, immunomodulatory agent and also is investigated for treating symptoms of many cancers. This compound inhibits cereblon (CRBN), a part of the cullin-4 E3 ubiquitin ligase complex CUL4-RBX1-DDB1.
Nat Genet, 2025, 57(10):2468-2481
Biomed Pharmacother, 2025, 184:117878
Nat Commun, 2024, 15(1):9195
Verified customer review of Thalidomide
S8975 Mezigdomide (CC-92480) Mezigdomide (CC-92480) is a novel protein degrader and a cereblon E3 ligase modulator (CELMoD) that has anti-myeloma activity.
Nat Commun, 2024, 15(1):8885
Mol Cancer Ther, 2023, 22(5):659-666
Mol Cancer Ther, 2023, 22(5):659-666
E1427 MRT-2359 MRT-2359 is a potent degrader of GSPT1. It exhibits anti-tumor activity in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) cells.
E1413 DEG-77 DEG-77 is a cereblon-dependent degrader of IKZF2 and casein kinase 1α (CK1α). It blocks cell growth and delays leukemia progression in murine and human acute myeloid leukemia (AML) mouse models.